Rocket One Inc., formerly Hoth Therapeutics, does not currently carry a meaningful analyst price target. Major data providers list no one-year target estimate for the shares, reflecting a micro-cap with a market capitalization of only about $9.5 million and no established institutional research coverage. For that reason, this discussion does not rely on an analyst consensus.
Instead, the $1.00 price objective is drawn from an identifiable, publicly discussed threshold: Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a $1.00 minimum bid price. Rocket One regained compliance in June 2026 after its shares closed at or above $1.00 for 10 consecutive business days, but the company disclosed a new deficiency notice dated August 6, 2026, giving it 180 calendar days — until February 2, 2027 — to regain compliance or face potential delisting, possibly via a reverse stock split.
This makes $1.00 a realistic, well-defined benchmark: it is a concrete level the company itself is monitoring, it sits well above the current price, and it is not an arbitrary headline figure. It is a regulatory milestone rather than a valuation-based stock price target.
The shares closed at about $0.38 on November 10, 2026, near the bottom of a 52-week range of roughly $0.37 to $2.45. Reaching $1.00 would require a rise of about 163%, a very large move that would effectively more than double the current market value. The stock trades as a penny stock, with a market capitalization near $9.5 million and no positive earnings, so its price is driven largely by news flow, financing activity, and retail sentiment rather than conventional valuation.
The company has been active in announcements. It reached an agreement with NASA to advance space AI technology, signed a patent license with the U.S. Air Force, joined the Seagate partner program, launched a drone-swarm threat emulation platform, and reported positive Phase 2a efficacy results for its HT-001 drug candidate. These headlines have periodically lifted the shares, but the stock has repeatedly faded back toward the $0.37–$0.40 area. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The most direct catalyst is regulatory: management has a clear incentive to keep the shares above $1.00 to preserve the Nasdaq listing, and it has indicated it may consider options including a reverse stock split to restore compliance. Beyond that, the company's repositioning toward radiation-tolerant, ultra-low-power nanomagnetic AI chip technology targets a genuinely growing orbital and defense computing market, and the string of government and industry agreements provides some early validation of its strategy.
The legacy biotech pipeline also retains optional value. The positive HT-001 Phase 2a readout and plans to pursue Phase 3 could, if partnered or financed separately, support sentiment. Finally, the shares' extreme volatility means that even modest, confirmed progress has historically produced outsized percentage moves in a stock with a float this small.
The obstacles are substantial. The company is pre-revenue in its space and AI business and loss-making, with a trailing twelve-month net loss of roughly $13.3 million and limited cash of about $7.9 million. Its nanomagnetic chip technology has not yet been fabricated as an integrated device, validated in space, or qualified for any commercial or government program.
Financing is another headwind. Rocket One has expanded its at-the-market equity offering program, which can dilute existing shareholders and has historically pressured micro-cap share prices. There is also genuine delisting risk: if the bid price does not return to $1.00 for 10 consecutive business days by the February 2, 2027 deadline, the company may need a reverse split, which often coincides with further weakness. Finally, competition from far larger, better-funded semiconductor and defense contractors remains a structural challenge.
The shares are testing a durable support zone near $0.37, the 52-week low, while $0.50 has acted as resistance during the October-to-November pullback. Above that, $1.00 is the key psychological and regulatory level: the stock spent several days above it in mid-2026 before falling back. A sustained close above $1.00 would mark both a technical and a listing-compliance milestone, whereas a break below $0.37 would open the door to new lows and intensify delisting pressure.
Because there is no analyst coverage, there is no standard 12-month research horizon to reference. The most relevant near-term date is the February 2, 2027 Nasdaq compliance deadline. Investors should monitor the bid price's ability to hold above $1.00 for 10 consecutive business days, the pace of cash burn and any new equity issuance, progress on the nanomagnetic chip and NASA, Air Force, and Seagate relationships, and further data or partnership news on the HT-001 program. Quarterly results and any reverse-split or compliance announcements will be the most direct signals on the path toward $1.00.
The question of whether Rocket One can reach $1.00 is ultimately a question about Nasdaq listing compliance as much as business fundamentals. The $1.00 objective is not an analyst-derived price target — there is no meaningful analyst coverage — but a regulatory threshold the company has a concrete deadline to reclaim. A 163% move is very large, and the path is complicated by losses, dilution, and pre-revenue technology. At the same time, the stock's small float, its recent government and industry agreements, and management's strong incentive to protect the listing mean sharp moves are possible in either direction. Investors should watch the cash position, new equity issuance, the compliance deadline, and the pace of technology and biotech milestones rather than treat $1.00 as a guaranteed outcome.
In my own research process, I have found Tickeron's AI Daily Buy/Sell Signals helpful for monitoring volatile names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. For micro-caps where momentum can shift rapidly, it offers a structured way to track trends alongside a broader watchlist without relying solely on manual chart review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RKTO saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 81 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for RKTO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 37 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RKTO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RKTO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where RKTO advanced for three days, in 145 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
RKTO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.217) is normal, around the industry mean (16.360). P/E Ratio (-0.491) is within average values for comparable stocks, (53.310). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.696). Dividend Yield (0.000) settles around the average of (0.434) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (104.492).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. RKTO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RKTO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company to develop therapeutics for patients suffering from eczema
Industry ComputerCommunications